Clinical trialObservationalCompleted
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
- Outcome
- Finished, no results posted
- Phase
- Observational
- Status
- Completed
- Study type
- Observational
- Start
- 28 March 2019
- Ended
- 31 December 2025
- Enrollment
- 420 participants
- Sites
- 1
- Primary outcomes
- Clinical applicability of KRAS mutations; Discovery of biomarkers through ctDNA panel
- Sponsor type
- Other government
- Results posted
- No
- Last update
- 9 April 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Detailed description public domain (ClinicalTrials.gov)
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. * Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples. * Correlation analysis of KRAS mutation results with clinical data. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. * Gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients. * Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Primary outcome public domain (ClinicalTrials.gov)
Clinical applicability of KRAS mutations. Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. Time frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months.
Primary outcome public domain (ClinicalTrials.gov)
Discovery of biomarkers through ctDNA panel. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. Time frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: * Patients with pathologically confirmed pancreatic adenocarcinoma. Exclusion Criteria: * Patients disagree with the study.
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 420 participants (actual).